Sorafenib: where do we go from here? - Wikidata - wikimedia - TriplyDB

Sorafenib: where do we go from here?

Sorafenib: where do we go from here?

http://www.wikidata.org/entity/Q36708741

about

STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver Hepatocellular carcinoma: Where there is unmet need Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis.Targeted therapy in hepatocellular carcinoma Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo.Downregulation of ANP32B exerts anti-apoptotic effects in hepatocellular carcinoma Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375 Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment.The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.Mouse models for liver cancer.Treatment of hepatocellular carcinoma: present and future.Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis.Developments in cancer vaccines for hepatocellular carcinoma.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives

P2860

Q27000742-FBB48801-6781-4181-966C-B43168C1B78F Q28084046-B2C6953C-070E-4555-9956-60A26F78C6A1 Q28384683-D492B89D-96B8-47E2-8336-C99612D451BD Q28540910-4A9789F5-CC15-4FCB-90EA-AED453089E59 Q33412612-B7E9EE0E-EE5B-4965-816B-A61CEC940DF7 Q33614172-CF952CB5-4B09-45AB-985C-F5FE03806CE4 Q34013776-A69E9A34-F466-4B1F-8A21-3534B4659A87 Q34241371-1DA01215-ECE2-42F9-929D-B845D4C57AB3 Q34827556-9AA3D2EE-D72F-4FB4-9D89-E219CD452795 Q35167959-C738C085-AB6F-4A53-93A4-4B3AEB23C9F2 Q35207561-653DD253-11D5-4B9C-B15E-C3AB81EB8500 Q35740345-B59AEFFC-D41B-49F8-934D-1D728CF15226 Q35914942-45320F1D-A76E-4273-86CF-3FE47EE80620 Q36226732-D0CD74C0-986A-4336-AD02-BB88523DDB9B Q36256549-0AD4BC0A-6E47-4CB6-8DA9-97FD0AE8ADDD Q36367144-0392C23D-D4B8-4F73-87FE-80C02495A3F5 Q36372357-3568C024-E0B4-4ACA-B381-E2457F672E08 Q36423166-EE1ECB06-00DB-40F2-82AD-96CA57ACF32C Q36684583-4FB655EF-8AB0-460B-867B-7213857AE66A Q36729450-A8679C20-5473-4C77-8381-BBA6F356A86C Q37076019-E414B367-96F3-4A03-857C-5956BCE126F8 Q37301893-48D26AF5-7407-4541-AB56-C70E55AFA99B Q37399436-D80551AF-1D40-415F-BA21-C638829B087D Q37413127-CB5C8136-BF4E-4C6D-9CC4-D9B9834D439F Q37493227-3B856EB1-5EE9-41BF-BD37-00EABC87AC6A Q37857056-A9B9D9DD-B3B4-4DC5-A6ED-3609AC99DF4F Q37914633-D94B6F69-201A-457C-837A-1E1975321842 Q37989160-DDD2AA50-7DBD-46BA-8566-D18357B3A9C8 Q38083387-FE8EF77D-14DA-4978-929F-B70CB4042105 Q38096477-F3118B34-2697-44B6-8523-B5864E70AAA1 Q38447668-23207209-1A69-4BB8-8651-F51D9B6E2DBB Q38533017-2D7B88C4-3C22-48AD-A65E-73986FCF23EA Q38635474-02AA4241-FCD0-469B-AE80-4FB152D00F58 Q38652256-8E8CE85B-0900-4700-936C-F510C79DAB26 Q38701634-086C8AFB-2C63-4E81-AD2C-193B5C7AF242 Q38743727-2F09DD39-A124-4619-8B0F-17AABC5000F5 Q39356122-A6556957-7DE4-4A1B-93B8-14A5C164F958 Q39546437-E3A48419-41C4-4184-9854-DB8FF8FAB7E1 Q41544681-9E03B63C-60FB-4DE0-9FDA-AB75760B7AEA Q41706847-5546DFD8-AC7F-4791-9DC0-1AFC10913CCD

P2860

Sorafenib: where do we go from here?

http://www.wikidata.org/entity/Q36708741

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Sorafenib: where do we go from here?

@ast

Sorafenib: where do we go from here?

@en

type

label

Sorafenib: where do we go from here?

@ast

Sorafenib: where do we go from here?

@en

prefLabel

Sorafenib: where do we go from here?

@ast

Sorafenib: where do we go from here?

@en

P1433

Q36708741-7D42F6C0-D60C-4AFB-AC50-77EEC3E66241

P1476

Q36708741-E09619D9-3ED4-4FB5-A29E-259C0075AFFC

P2093

Q36708741-60D201BE-DCBD-4282-9CBB-4FEAA27D2995

Q36708741-921A4306-77CB-41BE-96BC-0B9D2CE9EC36

Q36708741-98C4E599-2AE8-491A-8687-BD25DCC18CED

Q36708741-EFE76964-8B6C-4663-914E-976E5513410C

P2860

Q36708741-011C0895-2210-42A1-A1D5-EABD2C70479A

Q36708741-04F09532-89C1-44D4-A0AC-760A50154FB9

Q36708741-08666272-1932-4F23-96F0-8EAAE56FAFA1

Q36708741-0ACE5211-2806-4431-BE2B-707D66BDBD0A

Q36708741-0CC61D83-4E94-47A7-B8EF-A93EFBDB2F3C

Q36708741-0D2D17DC-A2AE-423E-88BD-682F66FD7017

Q36708741-0E7B3FD4-075C-4920-9542-B16D0801E1E3

Q36708741-0EF74EAD-84A7-4A5B-8700-A9EF80517F2E

Q36708741-1C98BE3A-3210-4A95-89DD-96748524CAAD

Q36708741-1E3C8D7B-7FDE-4F5D-9887-B4F53A8487C4

P304

Q36708741-0F3334D8-FAB9-4BFB-B8C3-5E955B89C5C7

P31

Q36708741-372FC7D1-7A91-46BB-BD06-A5ED6B75F923

P356

Q36708741-F7C26A80-020E-4DF6-B2A3-F9B735C3A47D

P407

Q36708741-EDF0337A-994E-48EB-8CE0-1B5508DD836D

P433

Q36708741-92F519B6-365D-4B1C-A2C1-B1CB1D669D5F

P478

Q36708741-E505774D-EF30-4B76-A2CE-0472868A197A

P577

Q36708741-39DFC7C7-2B75-47B1-8090-E5A8E6148CB6

P5875

Q36708741-F8D33014-B0D6-4FBC-B608-F660FFB8A44F

P698

Q36708741-21944850-C9C2-4BEC-9B46-008C9EB72556

P932

Q36708741-F4723D19-A780-48E0-B04F-D539ED6626E2

P356

P1433

P1476

Sorafenib: where do we go from here?

@en

P2093

Abby B Siegel

http://www.w3.org/2001/XMLSchema#string

Arthur Magun

http://www.w3.org/2001/XMLSchema#string

Robert S Brown

http://www.w3.org/2001/XMLSchema#string

Sonja K Olsen

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link

MicroRNA expression, survival, and response to interferon in liver cancer

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Sorafenib in advanced hepatocellular carcinoma

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor rec

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

P304

360-369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23633

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44800150

http://www.w3.org/2001/XMLSchema#string

P698

20578152

http://www.w3.org/2001/XMLSchema#string

P932

3605708

http://www.w3.org/2001/XMLSchema#string